Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue
Complete third-quarter 2026 financial results are expected to be reported at a later date.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Interpace Biosciences (IDXG) expects preliminary, unaudited third-quarter 2026 revenue to range from $10.1 million to $10.4 million.
The estimate covers the quarter ended September 30, 2026. The company expects growth of approximately 11% to 14% compared with second-quarter 2026 revenue of $9.1 million, and approximately 15% to 18% compared with third-quarter 2025 revenue of $8.8 million.
The revenue estimate is based on information currently available to management. It remains subject to completion of quarter-end closing procedures and review by the company’s independent registered public accounting firm. The company cautions that actual results could differ materially from the estimated range; these figures are not complete quarterly financial results.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Preliminary Q3 2026 revenue expected at $10.1 million–$10.4 million, approximately 11%–14% above Q2 2026 and 15%–18% above Q3 2025.
Negative
- Minor pointPreliminary, unaudited revenue remains subject to quarter-end closing procedures and independent accounting firm review.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Preliminary Q3 2026 revenue expected to range from
$10.1 million to$10.4 million - Expected quarter-over-quarter growth of approximately
11% to14% compared with Q2 2026 - Expected year-over-year growth of approximately
15% to18% compared with Q3 2025
PARSIPPANY, NJ, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCID: IDXG) today announced that it expects preliminary, unaudited revenue for the third quarter ended September 30, 2026 to range from
The expected revenue range represents an increase of approximately
The estimated revenue presented in this release is preliminary and unaudited, is based on information currently available to management, and remains subject to completion of the Company’s quarter-end closing procedures and review by the Company’s independent registered public accounting firm. Actual results may differ, including materially, from the range presented above. The Company expects to report complete financial results for the third quarter of 2026 at a later date.
About Interpace Biosciences
Interpace Biosciences is an emerging leader in enabling personalized medicine through specialized molecular diagnostic tests and related services. The Company’s commercialized thyroid tests include ThyGeNEXT® and ThyraMIR®v2, which are used together to support the evaluation of indeterminate thyroid nodules. For more information, please visit www.interpace.com.
Free Writing Prospectus
The issuer has filed a registration statement (including a prospectus) with the Securities and Exchange Commission (SEC) for the offering to which this free writing prospectus communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling 612-326-1305. You may also access the registration statement (including the prospectus) through the following link:
https://www.sec.gov/Archives/edgar/data/1054102/000149315226045187/forms-1a.htm
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable federal securities laws, including statements regarding the Company’s expected revenue for the third quarter of 2026 and the timing of its complete financial results. These statements are based on management’s current expectations and information available as of the date of this release and are subject to risks, uncertainties, closing adjustments and other factors that could cause actual results to differ materially. Such factors include those described under “Risk Factors” in the Company’s filings with the Securities and Exchange Commission. The preliminary, unaudited financial information in this release has not been reviewed by the Company’s independent registered public accounting firm and is subject to change as the Company completes its quarter-end closing and review procedures. The Company’s expected revenues for the third quarter of 2026 may not be indicative of the Company’s net income for such period or for full year results. Readers should not place undue reliance on these forward-looking statements. The Company undertakes no obligation to update any forward-looking statement, except as required by law.
Contacts
Investor Relations
Interpace Biosciences, Inc.
(855) 776-6419
Info@Interpace.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What revenue does Interpace Biosciences expect for the third quarter of 2026?
Interpace Biosciences expects preliminary, unaudited revenue of $10.1 million to $10.4 million for the quarter ended September 30, 2026. That represents approximately 11% to 14% growth compared with second-quarter 2026 revenue of $9.1 million and approximately 15% to 18% growth compared with third-quarter 2025 revenue of $8.8 million.